Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report

Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report

Lung cancer stands as a leading cause of mortality in China, with EGFR mutations frequently identified as pivotal driver genes. Osimertinib, a tyrosine kinase inhibitor targeting EGFR mutations, is typically employed as a first-line treatment for EGFR-sensitive mutations; nevertheless, resistance ca...

Full description

Bibliographic Details
Main Authors: Siqi Xiang, Liang Zeng, Mingjun Xiang, Yongchang Zhang
Format: Article
Language:English
Published: Elsevier 2023-11-01
Series:Heliyon
Subjects:
MET exon 14 skipping
MET fusion
Resistance mechanism
Osimertinib
Capmatinib
EGFR
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844023097232

Internet

http://www.sciencedirect.com/science/article/pii/S2405844023097232

Similar Items